Renal Denervation

Data Presented at the 2025 TCT Conference from the Real-World Global Paradise System Registry Show a Significant and Meaningful BP Reduction at 6 Months, and a Pooled Data Analysis from the RADIANCE Clinical Trial Program Demonstrates a 15.7...

Recor Medical, Inc., News Palo Alto, Calif. – Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced that the Centers for Medicare and Medicaid Services (CMS) has issued its National Coverage...

The Symplicity blood pressure procedure is an innovative, minimally invasive procedure that uses a single thin tube to deliver radiofrequency energy to calm the nerves near the kidneys that can become overactive and cause elevated blood...

The Paradise uRDN system is a novel ultrasound-based renal denervation technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension.

“We are pleased to see that the strength of our RADIANCE Global Program formed the basis for the positive inclusion in the guidelines, which not only reinforce the credibility of this therapy—they directly align with the compelling clinical...

The new ACC/AHA hypertension guidelines classify renal denervation procedures - like those using the Medtronic Symplicity Spyral™ renal denervation system - as a class IIb recommendation. These guidelines follow earlier consensus statements...

The first patient was treated by Dr. Barry Bertolet at Cardiology Associates of North Mississippi and North Mississippi Medical Center in Tupelo. With this trial, Medtronic intends to investigate the feasibility of combined denervation of...